A budget-impact and cost-effectiveness model for second-line treatment of major depression

Journal of Managed Care Pharmacy

Volumn 13, Issue 6 SUPPL. A, 2007, Pages

  Malone, Daniel C ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

Antidepressants; Budget impact model; Cost effectiveness model; Major depressive disorder; Managed care; SNRI (serotonin norepinephrine reuptake Inhibitor); SSRI; Venlafaxine extended release (XR)

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GENERIC DRUG; PAROXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; BEHAVIOR THERAPY; BUDGET; CLINICAL TRIAL; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG DOSE TITRATION; DRUG MARKETING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECONOMIC EVALUATION; HAMILTON SCALE; HUMAN; INCIDENCE; MAJOR DEPRESSION; MANAGED CARE ORGANIZATION; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PATIENT COMPLIANCE; REMISSION; SCORING SYSTEM; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 34548359357     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2007.13.s6-a.8     Document Type: Article

References (71)

1. Han D, Wang ECY. Remission from depression: a review of venlafaxine clinical and economic evidence. Pharmacoeconomics. 2005;23(6):567-81.
2. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry. 1993;54(11):405-18.
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-75.
4. Simon GE, Katon W, Rutter C, et al. Impact of improved depression treatment in primary care on daily functioning and disability. Psychol Med. 1998;28(3):693-701.
5. Druss BG, Schlesinger M, Allen HM Jr. Depressive symptoms, satisfaction with health care, and 2-year work outcomes in an employed population. Am J Psychiatry. 2001;158(5):731-34.
6. Kessler RC, Barber C, Birnbaum HG, et al. Depression in the workplace: effects on short-term disability. Health Aff. 1999;18(5):163-71.
7. Stewart WF, Ricci JA, Chee E, Hahn SR, Morganstein D. Cost of lost productive work time among US workers with depression. JAMA. 2003;289(23): 3135-44.
8. Osby U, Brandt L, Correia N, Ekbom A, Sparen P. Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58(9):844-50.
9. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
10. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Hamilton depression rating scale in healthy controls: implications for the definition of remission in treatment studies of depression. J Nerv Ment Dis. 2004;192(9):595-601.
11. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382-89.
12. Trivedi MH, Rush AJ, Wisniewski SR, et al. Factors associated with health-related quality of life among outpatients with major depressive disorder: a STAR*D report. J Clin Psychiatry. 2006; 67(2):185-95.
13. Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry. 2000;157(9):1501-04.
14. Miller IW, Keitner GI, Schatzberg AF, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry. 1998;59(11):608-19.
15. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol Med. 1995;25(6):1171-80.
16. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry. 1992;149(8):1046-52.
17. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55(8):694-700.
18. Frank E, Prien RF, Jarrett RB, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):851-55.
19. Ballenger JC. Clinical guidelines for establishing remission in patients with depression and anxiety. J Clin Psychiatry. 1999;60(suppl 22):29-34.
20. Schweitzer I, Burrows G, Tuckwell V, et al. Sustained response to open-label venlafaxine in drug-resistant major depression. J Clin Psychopharmacol. 2001;21(2):185-89.
21. Zimmerman M, Chelminski I, Posternak M. A review of studies of the Montgomery-Asberg Depression Rating Scale in controls: implications for the definition of remission in treatment studies of depression. Int Clin Psychopharmacol. 2004;19(1):1-7.
22. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-41.
23. Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J. Selective serotonin reuptake inhibitors (SSRIs) versus other antidepressants for depression (review). Cochrane Database Syst Rev. 07/15/1999 1999 (4 Art No. CD001851).
24. Gartlehner G, Hansen RA, Lohr KN, et al. Comparative effectiveness of second-generation antidepressants in the pharmacologic treatment of adult depression. Comparative Effectiveness Review No. 7. Rockville, MD: Agency for Healthcare Research and Quality; January 2007. Available at: www.effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed April 20, 2006.
25. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143(6):415-26.
26. Barrett B, Byford S, Knapp M. Evidence of cost-effective treatments for depression: a systematic review. J Affect Disord 2005;84(1):1-13.
27. Le Pen C, Levy E, Ravily V, Beuzen JN, Meurgey F. The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine vs. tricyclics. J Affect Disord. 1994;31(1):1-18.
28. Nuijten MJ, Hardens M, Souêtre E. A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression. Pharmacoeconomics. 1995;8(2):159-68.
29. Kind P, Sorensen J. Modelling the cost-effectiveness of the prophylactic use of SSRIs in the treatment of depression. Int Clin Psychopharmacol. 1995;10 (suppl 1):41-48.
30. Wade AG, Toumi I, Hemels MEH. A pharmacoeconomic evaluation of escitalopram versus citalopram in the treatment of severe depression in the United Kingdom. Clin Ther. 2005;27(4):486-96.
31. Demyttenaere K, Hemels MEH, Hudry J, Annemans L. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther. 2005;27(1):111-24.
32. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness analysis of escitalopram: a new SSRI in the first-line treatment of major depressive disorder in Austria. Curr Med Res Opin. 2004;20(6):869-78.
33. Kulp W, von der Schulenburg JMG, Greiner W. Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. Eur J Health Econ. 2005;6(4):317-21.
34. Fernandez J-L, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics. 2005;23(2):155-67.
35. Sullivan PW, Valuck R, Saseen J, MacFall HM. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs. 2004;18(13):911-32.
36. McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM Jr., Gross LS. The cost of antidepressant drug therapy failure: a study of antidepressant use patterns in a Medicaid population. J Clin Psychiatry. 1990;51(suppl):60-69; discussion 70-71.
37. Revicki DA, Siddique J, Frank L, et al. Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry. 2005;62(8):868-75.
38. Lenox-Smith A, Conway P, Knight C. Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics. 2004;22(5):311-19.
39. Trivedi MH, Wan GJ, Mallick R, et al. Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. J Clin Psychopharmacol. 2004;24(5):497-506.
40. Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry. 2003;64(3):321-30.
41. Foundation for Managed Care Pharmacy. AMCP Format for Formulary Submissions. Version 2.1. A format for submission of clinical and economic data in support of formulary consideration by health care systems in the United States. Alexandria, VA: Foundation for Managed Care Pharmacy; 2005.
42. Simon GE, Khandker RK, Ichikawa L, Operskalski BH. Recovery from depression predicts lower health services costs. J Clin Psychiatry. 2006;67 (8):1226-31.
43. Verispan. Longitudinal data. MAT. July 2005.
44. Allard P, Gram L, Timdahl K, Behnke K, Hanson M, Sogaard J. Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. Int J Geriatr Psychiatry. 2004;19(12):1123-30.
45. Galecki P, Florkowski A, Pietras T, et al. Efficiency and safety of citalopram and venlafaxine in treatment of depressive disorders in elderly patients [in Polish]. Pol Merkuriusz Lek. 2004;17(102):621-24.
46. Dierick M, Ravizza L, Realini R, Martin A. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20(1):57-71.
47. Silverstone PH, Ravindran A. Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety Venlafaxine XR 360 Study Group. J Clin Psychiatry. 1999;60(1):22-28.
48. Tzanakaki M, Guazzelli M, Nimatoudis I, Zissis NP, Smeraldi E, Rizzo F. Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia [erratum appears in Int Clin Psychopharmacol. 2000;15(2):120]. Int Clin Psychopharmacol. 2000;15(1):29-34.
49. De Nayer A, Geerts S, Ruelens L, et al. Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety. Int J Neuropsychopharmacol. 2002;5(2):115-20.
50. Alves C, Cachola I, Brandao J. Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression. Prim Care Psychiatry. 1999;5:57-63.
51. Tylee A, Beaumont G, Bowden MW, et al. A double-blind, randomised, 2-week comparison study of the safety and efficacy of venlafaxine and fluoxetine in moderate to severe depression in general practice. Prim Care Psychiatry. 1997;3:51-58.
52. Costa e Silva J. Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression. J Clin Psychiatry. 1998;59(7):352-57.
53. Montgomery SA, Huusom AKT, Bothmer J. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology. 2004;50(1):57-64.
54. Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65(9):1190-96.
55. Hwang J-P, Yang C-H, Tsai S-J. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Int J Geriatr Psychiatry. 2004;19(2):189-90.
56. Vieta E, Martinez-Aran A, Goikolea JM, et al. A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers. J Clin Psychiatry. 2002;63(6):508-12.
57. Ballus C, Quiros G, De Flores T, et al. The efficacy and tolerability of venlafaxine and paroxetine in outpatients with depressive disorder or dysthymia. Int Clin Psychopharmacol. 2000;15(1):43-48.
58. McPartlin GM Reynolds A, Anderson C, Casoy J. A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practice. Prim Care Psychiatry. 1998;4:127-32.
59. Oslin DW, Ten Have TR, Streim JE, et al. Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents. J Clin Psychiatry. 2003;64(8):875-82.
60. Mehtonen OP, Sogaard J, Roponen P, Behnke K. Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group. J Clin Psychiatry. 2000;61(2):95-100.
61. Clerc GE, Ruimy P, Verdeau-Palles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group. Int Clin Psychopharmacol. 1994;9(3):139-43.
62. Baldomero EB, Ubago JG, Cercos CL, Ruiloba JV, Calvo CG, Lopez RP. Venlafaxine extended release versus conventional antidepressants in the remission of depressive disorders after previous antidepressant failure: ARGOS study. Depress Anxiety. 2005;22(2):68-76.
63. Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry. 2002;63(4):331-36.
64. Thase ME, Blomgren SL, Birkett MA, Apter JT, Tepner RG. Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline. J Clin Psychiatry 1997;58(1):16-21.
65. Mitchell PB, Schweitzer I, Burrows G, Johnson G, Polonowita A. Efficacy of venlafaxine and predictors of response in a prospective open-label study of patients with treatment-resistant major depression. J Clin Psychopharmacol. 2000;20(4):483-87.
66. de Montigny C, Silverstone PH, Debonnel G, Blier P, Bakish D. Venlafaxine in treatment-resistant major depression: a Canadian multicenter, open-label trial. J Clin Psychopharmacol. 1999;19(5):401-06.
67. Nierenberg AA, Feighner JP, Rudolph R, Cole JO, Sullivan J. Venlafaxine for treatment-resistant unipolar depression. J Clin Psychopharmacol. 1994; 14(6):419-23.
68. Kaplan EM. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study. Clin Ther. 2002;24(7):1194-1200.
69. Saiz-Ruiz J, Ibañez A, Diaz-Marsa M, et al. Efficacy of venlafaxine in major depression resistant to selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1129-34.
70. Hemels MEH, Kasper S, Walter E, Einarson TR. Cost-effectiveness of escitalopram versus citalopram in the treatment of severe depression [erratum appears in Ann Pharmacother. 2004;38(9):1545]. Ann Pharmacother. 2004;38(6):954-60.
71. Wade AG, Toumi I, Hemels MEH. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin. 2005;21(4):631-42.